Ilyas Sahin, Assistant Professor at Harvard Medical School, shared on X:
“Should inherited genetic testing be offered to everyone diagnosed with cancer?
A new Cancer Discovery study tested 39,184 patients across 32 solid tumor types. Overall, 16.3% carried a pathogenic germline variant.
Using age 50 alone as the cutoff would have missed 72% of carriers. Even among late-onset cancers, 12.3% had a pathogenic variant, including 5.1% in high- or moderate-penetrance genes.
The question may no longer be whether we will find these variants, but how to make testing actionable, accessible, and affordable.”
Title: Universal Germline Genetic Testing after a Diagnosis of Cancer
Authors: Zsofia K. Stadler, Anna Maio, Aliya Khurram, Kanika Arora, Chaitanya Bandlamudi, Ying L. Liu, Yelena Kemel, Margaret Sheehan, Erin Salo-Mullen, Angelika Padunan, Tina Alano, William D. Tap, Julia L. Glade Bender, Andrea Cercek, Ingo K. Mellinghoff, Eileen M. O’Reilly, Alan L. Ho, Michael D. Offin, Alexander N. Shoushtari, Chimene A. Kesserwan, Mohammad Abbass, Lauren Banaszak, Lisa M. DeAngelis, Yonina R. Murciano-Goroff, Marc Ladanyi, Ozge Ceyhan-Birsoy, Maria I. Carlo, Alicia Latham, Mark E. Robson, David B. Solit, Michael F. Berger, Diana L. Mandelker, Kenneth Offit, Luis A. Diaz Jr.
Read the Full Article on Cancer Discovery
You can also read: Muna Al-Khaifi: What BRCA1 and BRCA2 Testing Reveals About Lifetime Cancer Risk
